Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages-Reference-Cited by-同舟云学术

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages

Published:2022-08 Issue:8 Volume:30 Page:1077-1083.e4
ISSN:1931-3128
Container-title:Cell Host & Microbe
language:en
Short-container-title:Cell Host & Microbe

Author:

Ai Jingwen,Wang Xun,He Xinyi,Zhao Xiaoyu,Zhang Yi,Jiang Yuchao,Li Minghui,Cui Yuchen,Chen Yanjia,Qiao Rui,Li Lin,Yang Lulu,Li Yi,Hu Zixin,Zhang Wenhong,Wang Pengfei^ORCID

Publisher

Elsevier BV

Subject

Virology,Microbiology,Parasitology

Reference40 articles.

1. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost;Ai;Emerg. Microbes Infect.,2021

2. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines;Bowen;bioRxiv,2022

3. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift;Cameroni;Nature,2022

4. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies;Cao;Nature,2022

5. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada;Carazo;Clin. Infect. Dis.,2021

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination;Cell Discovery;2024-02-06

2. Development of SARS-CoV-2 entry antivirals;Cell Insight;2024-02

3. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants;Viruses;2024-01-31

4. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1;Journal of Virology;2024-01-23

5. In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates;Emerging Microbes & Infections;2024-01-02